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Review

A review of osteoporosis management in
younger premenopausal women
Amber N McLendon*1 & C Brock Woodis2
The purpose of this review is to describe the available evidence for osteoporosis treatments in
young and premenopausal women. A review of articles evaluating the treatment or prevention of
osteoporosis in young (age less than 50 years) or premenopausal women was conducted. Several
trials evaluating the treatment of anorexia nervosa and use of hormone therapy in those women,
the use of bisphosphonates in women undergoing chemotherapy for breast cancer and the use
of bisphosphonates, teriparatide and vitamin D in women with glucocorticoid-induced osteoporosis
are described. Limited data were found to support the treatment of osteoporosis in women with
idiopathic osteoporosis or cystic fibrosis, or after kidney transplant. The evidence for treatment of
osteoporosis in premenopausal women is not nearly as robust as that for postmenopausal
osteoporosis. Although fracture risk in the premenopausal population is low, women with
secondary osteoporosis may benefit from treatment with various agents, depending upon the
condition.

Osteoporosis in younger women results from
either a low peak bone mass, increased bone
loss prior to menopause or both [1] . Peak bone
mass is reached by 30 years of age with 90% of
the development completed by 18 years of age
[2] . For most women, bone mass remains stable
until menopause, when the loss of estrogen in
conjunction with aging is associated with a
decline in bone mineral density (BMD). Family history, gender and race are responsible for
the majority of peak bone mass; however, diet
and exercise behaviors are responsible for up to
25%. Peak bone mass variations are genetic in
60–70% of cases [3] . Osteoporosis is a disease
of the bone, with effects including decreased
BMD and increased risk of fractures, especially
at the spine, hip and wrist [4] . The loss of bone
results from an imbalance in bone formation by
osteoblasts and bone resorption by osteoclasts.
Most treatments for osteoporosis aim to adjust
this imbalance [5] . In the case of premenopausal
osteoporosis, secondary causes are responsible
for at least half of cases [1] . Secondary causes are
listed in Table 1 [1] . In the Michigan Bone Health
Study, over 600 premenopausal women followed
for 6 years showed varied changes in lumbar
spine (LS) BMD but a 1.6% decrease in femoral
neck (FN) BMD starting in a woman’s mid 20s
[6] . Risk factors for low BMD in premenopausal
women include low body weight, amenorrhea,
lack of physical activity, smoking, low dietary
calcium or vitamin D, personal or family history of fracture, pregnancy and Caucasian or
Asian race [3] . Minimal bone loss is noted during
pregnancy and breastfeeding; however, this loss
10.2217/WHE.13.73 © 2014 Future Medicine Ltd

is usually corrected shortly after pregnancy and
breastfeeding are complete [7] .
Healthy premenopausal women experience a
0.25–1% loss in BMD annually after reaching
peak bone mass (commonly at the FN); however, no link has been established between this
gradual loss in BMD and fracture risk in healthy
women. Low Z-scores (2.5 standard deviations
below other young females) are seen in 0.5% of
premenopausal women [3] . In Spanish women
20–44 years of age, 0.34% will have osteoporosis
at the LS and 0.17% will have osteoporosis at the
FN based on BMD alone [1] . Overall, 50–90%
of premenopausal women have a secondary cause
for osteoporosis (e.g., eating disorders or glucocorticoid use, among others), with the remaining
women diagnosed with idiopathic osteoporosis
[8] . Fracture risk in premenopausal women with
osteoporosis remains low due to the small baseline
fracture risk in younger women. The incidence of
fractures in females under the age of 35 years is
more difficult to detect due to the low incidence
of three fractures per 100,000 patient-years but is
noted to increase to 21 per 100,000 patient-years
in women aged 35–44 years [1] . Premenopausal
fractures are associated with a 1.5- to 3-fold
increase in the risk of postmenopausal fractures
[3] . Fracture risk is doubled or tripled once a loss
of 10% in BMD has occurred; however, treatments resulting in a 5% increase in BMD may
decrease fracture risk [9] .
Premenopausal women referred to a bone disease referral program at a tertiary medical center
were evaluated for secondary versus idiopathic
osteoporosis [10] . A retrospective review of all
Women's Health (2014) 10(1), 59–77
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Table 1. Secondary causes of osteoporosis in young women.
Causes

Examples

Medications

Glucocorticoids, anticonvulsants, aromatase
inhibitors, heparin, alcohol, LHRH agonists,
medroxyprogesterone acetate, high-dose
levothyroxine, cytotoxic chemotherapy

Endocrine diseases

Hypogonadism, hyperthyroidism, Cushing’s
disease, growth hormone deficiency,
hypopituitarism, hyperparathyroidism, Type 1
diabetes

Malnutrition or malabsorption

Anorexia nervosa, inflammatory intestinal
disease, celiac disease, intestinal resection

Inflammatory disease

Rheumatoid arthritis, systemic lupus
erythematous

Transplant patients

Solid organ and bone marrow transplants

Other causes

Liver disease, osteogenesis imperfecta,
HIV infection, hemochromatosis, idiopathic
osteoporosis, pregnancy, systemic
mastocytosis, chronic kidney disease,
malignancies, hyperprolactinemia, multiple
myeloma, depression

LHRH: Luteinizing hormone-releasing hormone.
Data taken from [1,3].

premenopausal women referred for fracture or
low bone mass over 1 year (n = 61) was conducted, and 39% were found to have idiopathic
osteoporosis, while 49% of the 29 women with
a history of low-trauma fracture had idiopathic
osteoporosis. This is consistent with other measures in premenopausal women. Low-trauma
fracture was defined as that occurring due to
a fall from standing height or less, with the
exception of digit or skull fracture. Over half
of the women (57%) reported a family history
of osteoporosis. Secondary osteoporosis was due
to amenorrhea in 34%, anorexia nervosa (AN)
in 16%, glucocorticoid use in 13% and celiac
disease in 10%. Premenopausal women with
secondary osteoporosis had lower BMD at the
spine (Z-score: -2.39 vs -1.58; p = 0.001) and
hip than those with idiopathic osteoporosis,
indicating a greater need for treatment in those
women with secondary causes. Of the women
referred due to a fracture, 28% did not have
a low BMD. Bisphosphonates were used by
47% of women with low BMD but no history
of fracture and by 50% of women with idiopathic osteoporosis, which may indicate overuse
of osteoporosis treatments in this population.
Therefore, a need to clarify the role of osteoporosis treatments in younger, premenopausal
women is needed.
The purpose of this review is to describe the
available evidence for osteoporosis treatments
in young and premenopausal women (Table 2) .
60
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Diagnosis

The International Society for Clinical Densito
metry has developed standards for measuring
BMD in premenopausal women [11] . They advocate the use of Z-scores rather than T-scores
(used in postmenopausal women to describe
standard deviations from a young, normal
female BMD), with Z-scores of less than -2.0
at the LS or femur to determine BMD “below
the expected range for age.” The Z-score combined with risk factors including a history of
fragility fracture is then used to make a diagnosis of osteoporosis in this younger cohort. In
addition to BMD, a full medical history, family history, menstrual history, diet and exercise,
lifestyle, medication history and laboratory
workup should be performed to determine the
underlying cause [1,3] .
The US Preventive Services Task Force does
not recommend BMD screening in healthy
premenopausal women with no risk factors
for osteoporosis [3] . Women with AN or with
amenorrhea over 6 months to a year are recommended to obtain BMD screening, although the
results should be interpreted carefully, as many
of these young women have yet to reach peak
bone mass [9] .
Osteoporosis prevention in young
women

The National Osteoporosis Foundation recommends that women aged 18–50 years should consume 1000 mg of calcium and 600 IU of vitamin
D daily [2] . Regular weight-bearing exercise is
also associated with increased BMD. Other recommended lifestyle factors are to avoid smoking
and alcohol, and limit caffeine consumption.
A 2013 systematic review of calcium intake
and its effects on bone health concluded that
data supporting the benefits in premenopausal
women were limited, although positive effects
on BMD were found in children and post
menopausal women [12] . In comparison, calcium,
vitamin D and increased physical activity demonstrated a positive effect in 16 premenopausal
women (average age 36 years) with idiopathic
osteoporosis [13] . All secondary causes of osteoporosis were excluded. The study design was observational and followed women over an average
of 3 years. The subjects were instructed to take
calcium 500–1000 mg/day based on dietary calcium intake, take vitamin D 400–800 IU/day,
increase physical activity and avoid smoking.
The exact formulation and amount of calcium,
vitamin D and type and amount of exercise
for each subject was not reported. Half of the
future science group

future science group

Women's Health (2014) 10(1)

ZA 4 mg iv. every 6 months
Observational group

Ethinyl estradiol/norgestimate (n = 53)
Placebo (n = 59)

Estrogen/progesterone (n = 22)
Placebo (n = 26)

LS BMD: ↓1.1 vs 7.5% (p < 0.001); FN BMD: ↑1.1
vs ↓3.4% (p < 0.001)

6 months: LS BMD: 2.4 vs 1% (p = 0.013)
13 months: LS BMD: 3.1 vs 2.4% (NSS)

No difference between groups
Subjects that resume menses: ↑ BMD 19.3%

No difference between groups

[35]

[30]

[29]

[28]

[25]

[27]

[26]

AN: Anorexia nervosa; b.i.d.: Twice daily; BMD: Bone mineral density; Ca: Calcium; CF: Cystic fibrosis; FN: Femoral neck; GIO: Glucocorticoid-induced osteoporosis; HR: Hazard ratio; im.: Intramuscular; IU: International
units; iv.: Intravenous; LS: Lumbar spine; MPA: Medroxyprogesterone acetate; NSS: Not statistically significant; p.o.: Orally; QOD: Every other day; RA: Rheumatoid arthritis; RCT: Randomized controlled trial;
sc.: Subcutaneously; VitD: Vitamin D; ZA: Zoledronic acid.

Open label
(12 months)

112 premenopausal women undergoing
chemotherapy for breast cancer (n = 112;
age: >40 years)

112 women with AN (age: 15 years; LS
Z-score: -0.8; VitD: 400 IU; Ca: 500 mg)

RCT (13 months)

Breast cancer

48 women with AN and amenorrhea
(age: 24 years)

RCT (18 months)

Oral contraceptive/standard treatment with AN
50 women with AN (age: 16 years;
30 months (n = 22)
amenorrhea: 16 months; LS Z-score: -1.58; FN
T-score: -1.58; VitD: 400 IU; Ca: 1200–1500 mg) Standard treatment with AN 16 months (n = 28)

Observational
(1 year)

No difference between groups
Subjects that resumed menses: ↑ LS BMD 4%
(p = 0.008); ↑ hip BMD 3% (p = 0.05); ↑ FN
BMD 3% (p = 0.04)
Subjects that increased in weight: ↑ LS BMD
(p = 0.04); ↑ hip BMD (p = 0.04); ↑ LS BMD
(p = 0.04); ↑ hip BMD (p = 0.04)

17-b estradiol 0.5 mg days 1–21/dydrogesterone
10 mg days 11–21 (n = 12)
Control (n = 33)

45 women with AN and T-score <-2.5
(age: 25 years; AN for average 8 years;
amenorrhea: 7 years; LS Z-score: -2.3; FN
Z-score: -3.4; hip Z-score: -3.4
Ca/VitD only in those with deficiencies)

Longitudinal
cohort (2 years)

LS T-score: -1.8 (NSS)

No difference between groups
Controls that resumed menses: ↑ LS BMD 3.1%
(p = 0.02)
Controls that increased in weight: ↑ hip BMD
0.6% (p = 0.05)

Ethinyl estradiol 50 µg/norgestrel 0.5 mg

Oral contraceptive (n = 30)
Control (n = 45)

38 women with AN and amenorrhea for 1 year
(age: 17 years; LS T-score: -2.1)

75 women with AN (age: 24 years; LS T-score:
-1.8; hip T-score: -1.4)

Observational
cohort (1 year)

Observational

Anorexia nervosa

Osteopenia HR: 0.53 (95% CI : 0.37–0.76)
No fractures

[18]

Sedentary
Moderate exercise

71 premenopausal women with RA
29 controls (age: 38 years)

Ref.

Case–control
(2 years)

Results

[13]

Intervention

16 premenopausal women with idiopathic
Ca: 500–1000 mg (dose based on dietary intake) ↑ LS BMD 1.9% (p = 0.021)
osteoporosis (LS Z-score: -2.04; FN Z-score: -1.47) VitD: 400–800 IU
↑ FN BMD 5.6% (p = 0.04)
Increase physical activity and avoid smoking
No fractures

Population

Observational
(3 years)

Diet & exercise

Study type
(length)

Table 2. Evidence for treatment of osteoporosis in young, premenopausal women.

A review of osteoporosis management in younger premenopausal women –

Review
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231 subjects with GIO or at risk for GIO on

≥7.5 mg daily

201 subjects with GIO taking prednisone

35–50 years [n = 231]; premenopausal: n = 195;
VitD: 400–1200 IU; Ca: 1000 mg)

≥7.5-mg prednisone (age: <35 years [n = 86];

Alendronate 10 mg daily (n = 99; n = 7
premenopausal women)
Alphacalcidol 1 µg daily (n = 101; n = 10
premenopausal women)

ZA 5 mg iv. for one dose
Risedronate 5 mg p.o. daily

LS BMD ↑2.1 vs ↓1.9%; difference 4% (95% CI:
2.4–5.5%); hip BMD ↑1.4 vs ↓2%; difference
3.4% (95% CI: 1.3–5.5); vertebral fractures:
three vs 13; HR: 0.4 (95% CI: 0.1–1.4);
nonvertebral fractures two vs three; HR: 0.7
(95% CI: 0.1–4)

Total hip BMD: ZA > risedronate (p = 0.025)
Vertebral fractures: five vs three (NSS)
LS (age: 35–50 years) BMD: ZA > risedronate
(p = 0.0041)
Premenopausal women with GIO: ↑ LS BMD
3.1% ZA; ↑ LS BMD: 1.7% risedronate (NSS);
Total hip BMD ZA > risedronate (p = 0.025)
Premenopausal women at risk for GIO: ↑ LS BMD
1.8% ZA; ↑ LS BMD 0.7% risedronate (NSS);
total hip BMD ZA > risedronate (p = 0.049)

[47,49]

[47]

[42]

AN: Anorexia nervosa; b.i.d.: Twice daily; BMD: Bone mineral density; Ca: Calcium; CF: Cystic fibrosis; FN: Femoral neck; GIO: Glucocorticoid-induced osteoporosis; HR: Hazard ratio; im.: Intramuscular; IU: International
units; iv.: Intravenous; LS: Lumbar spine; MPA: Medroxyprogesterone acetate; NSS: Not statistically significant; p.o.: Orally; QOD: Every other day; RA: Rheumatoid arthritis; RCT: Randomized controlled trial;
sc.: Subcutaneously; VitD: Vitamin D; ZA: Zoledronic acid.

RCT (18 months)

RCT (1 year)

Glucocorticoid-induced osteoporosis

LS BMD 2.5% between groups (p = 0.041); FN
BMD 2.6% between groups (p = 0.029)

53 women with breast cancer and ovarian failure Risedronate 30 mg daily for 2 weeks every
12 weeks (n = 27)
Placebo (n = 26)

RCT (2 years)

[39]

LS BMD: ↓4.3 vs 5.4% (NSS)

Risedronate 35 mg weekly (n = 108)
216 premenopausal women with breast cancer
preparing for chemotherapy (age: 43 years; VitD: Placebo (n = 108)
400 IU; Ca: 600 mg)

RCT, Phase III
(1 year)

RCT (1 year; and
1-year follow-up)

[32,38]

401 premenopausal women with
hormone-responsive breast cancer undergoing
treatment

Open label,
Phase III (3 years;
and 2-year
follow-up)
LS BMD: ↓0.6 vs 4.39% (p < 0.05)
FN BMD: ↑0.4 vs ↓1.5% (p < 0.05)
Hip BMD: ↑2.8 vs ↓0.12% (p < 0.05)
1-year follow-up: LS BMD stable vs ↓ (p < 0.01);
hip BM stable vs ↓ (p < 0.01)

Ref.

103 premenopausal women with newly
ZA 4 mg iv. every 3 months (n = 50)
diagnosed breast cancer undergoing
Placebo (n = 53)
chemotherapy (age: 42 years; VitD: 400–800 IU;
Ca: 1000 mg)

Results

[36,37]

ZA 4 mg iv. every 6 months
Observational group

Intervention

LS BMD no change vs ↓14.4% (p < 0.001);
LS T-score no change vs ↓1.4
2-year follow-up: LS BMD ↑4% in treatment
(p = 0.02); LS BMD ↓6.6% in observational
group (p < 0.01); fractures zero vs two (NSS)

Breast cancer (cont.)

Study type
(length)

Table 2. Evidence for treatment of osteoporosis in young, premenopausal women (cont.).
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future science group

Population

future science group

20 premenopausal women with systemic lupus
erythematous and osteopenia taking prednisone
≥10 mg (age: 37 years; amenorrhea: 2 years;
Ca: 1000 mg)

RCT (24 months)

Women's Health (2014) 10(1)

80 subjects with kidney transplant (n = 13
premenopausal women; age: 43 years;
Ca: 1000 mg)

RCT (12 months)

Ibandronate iv. 1 mg before transplant and 2 mg ↓ LS BMD: 0.9 vs 6.5% (p < 0.001); FN BMD:
↑0.5% vs ↓7.7% (p < 0.0001)
3 months after transplant
Placebo

6 months to 3 years: Z-score ZA: -1.6 to -1.2
(p = 0.044); Z-score placebo: -1.3 to -0.2
(p = 0.021); vertebral fractures: two in each
group
[57]

[55,56]

[53]

LS BMD: ↑ 5.2 vs ↓0.08% (p < 0.001); hip BMD:
↑2.1 vs ↓1.3% (p < 0.001); fractures NSS

LS Z-score: ↑0.23 vs ↓0.27 (significant but no
p-value given); FN Z-score: ↑0.02 vs ↓0.57
(significant but no p-value given)

[54]

[52]

LS BMD ↑2% (p < 0.05 from baseline) vs ↓1.74%
(p < 0.05 from baseline; p < 0.03); no fractures

LS BMD: ↑4.9 vs ↓1.8% (p < 0.001); hip BMD:
↑2.8 vs ↓0.7% (p = 0.003); no fractures

[50,51]

Ref.

↑ LS BMD 7 vs 0.7% (p < 0.001); ↑ hip BMD 4 vs
1% (p < 0.01); vertebral fractures zero for both;
nonvertebral fractures two vs zero (p = 0.32)
Full study population at 36 months: ↑ LS BMD 11
vs 5.3% (p < 0.001); ↑ hip BMD: 5.2% vs 2.7%
(p < 0.001); ↑ FN BMD: 6.3 vs 3.4% (p < 0.001);
vertebral fractures: 1.7 vs 7.7% (p = 0.007)

Results

AN: Anorexia nervosa; b.i.d.: Twice daily; BMD: Bone mineral density; Ca: Calcium; CF: Cystic fibrosis; FN: Femoral neck; GIO: Glucocorticoid-induced osteoporosis; HR: Hazard ratio; im.: Intramuscular; IU: International
units; iv.: Intravenous; LS: Lumbar spine; MPA: Medroxyprogesterone acetate; NSS: Not statistically significant; p.o.: Orally; QOD: Every other day; RA: Rheumatoid arthritis; RCT: Randomized controlled trial;
sc.: Subcutaneously; VitD: Vitamin D; ZA: Zoledronic acid.

20 subjects with kidney transplant
(age: 49–55 years)

RCT (6 months;
and 3 year
follow-up)

ZA 4 mg iv. 2 weeks and 3 months after
transplant (n = 10; n = 4 women)
Placebo (n = 10; n = 4 women)

56 subjects with CF and T-score <-1 (subset of 22 Alendronate 70 mg weekly (n = 10)
Placebo (n = 10)
women; age: 29 years; LS T-score: -1.6;
VitD: 800 IU; Ca: 500 mg plus 500 mg diet)

RCT (12 months)

Kidney transplant

48 subjects with CF and LS/FN T-score ≤-1
(age: 27.5 years; LS T-score: -1.785; LS Z-score:
-1.695; VitD: 800 IU; Ca: 1000 mg)

Alendronate 10 mg daily (n = 24; n = 9 females)
Placebo (n = 24; n = 14 females)

Conjugated estrogens 0.625 mg days 1–21/MPA
10 mg days 11–21
Calcitriol 0.5 µg daily

Teriparatide 20 µg sc. daily (n = 37; age 40 years;
LS T-score -2.4; hip T-score -1.7; average
prednisone dose 8 mg for 1.8 years; history of
fracture 33%)
Alendronate 10 mg daily (n = 30; age 36 years;
LS T-score -2.6; hip T-score -1.8; average
prednisone dose 10 mg for 0.9 years; history of
fracture 28%)

Intervention

RCT (12 months)

Cystic fibrosis

428 subjects with GIO taking prednisone ≥5 mg
daily and LS/hip (subset of 67 premenopausal
women; T-score: ≤-2 or ≤-1 with fracture
VitD: 800 IU; Ca: 1000 mg)

RCT (18-month
interim with
subset population;
36 months total
for full study
population)

Glucocorticoid-induced osteoporosis (cont.)

Study type
(length)

Table 2. Evidence for treatment of osteoporosis in young, premenopausal women (cont.).

A review of osteoporosis management in younger premenopausal women –
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32 subjects with Crohn’s disease and hip T-score
<-1 (VitD: 400 IU; Ca: 1000 mg)

28 premenopausal women with oophorectomy
(Ca: 500 mg b.i.d.)

RCT (12 months)

RCT (6 months)

Salmon calcitonin 100 units im. QOD
Placebo

Alendronate 10 mg daily (n = 17)
Placebo (n = 15)

Parathyroid hormone 40 µg sc. daily (n = 20)
Placebo (n = 20)

[61]

[62]
[63]

LS BMD: ↑4.6 vs ↓0.9% (p < 0.01)
BMD stable in calcitonin group but ↓ in placebo
group

AN: Anorexia nervosa; b.i.d.: Twice daily; BMD: Bone mineral density; Ca: Calcium; CF: Cystic fibrosis; FN: Femoral neck; GIO: Glucocorticoid-induced osteoporosis; HR: Hazard ratio; im.: Intramuscular; IU: International
units; iv.: Intravenous; LS: Lumbar spine; MPA: Medroxyprogesterone acetate; NSS: Not statistically significant; p.o.: Orally; QOD: Every other day; RA: Rheumatoid arthritis; RCT: Randomized controlled trial;
sc.: Subcutaneously; VitD: Vitamin D; ZA: Zoledronic acid.

40 women with endometriosis treated with
gonadotropin-releasing hormone agonists (age:
30 years; Ca: 1200 mg)

RCT (6 months)

LS BMD: ↑3.4 (p = 0.01 from baseline) vs ↓2.8%
(p = 0.01 from baseline; p < 0.001 between
groups)
FN BMD NSS

[60]

LS BMD: ↓ 4.3% in Ca/VitD (p < 0.05 from
baseline); FN BMD: ↓ 4.2% in Ca/VitD (p < 0.05
from baseline); LS BMD stable in hormone
group; FN BMD stable in hormone group; LS
BMD: ↑5.8% in risedronate (p < 0.05 from
baseline); FN BMD: ↑1.2% in risedronate (NSS
from baseline); LS BMD: ↑ 8.6% in ZA (p < 0.01
from baseline); FN BMD: ↑ 5.4% in ZA (p < 0.05
from baseline)
Bisphosphonates vs hormone and Ca/VitD group
at LS: (p < 0.05); ZA vs risedronate at FN
(p < 0.001)

Calcium 1000 mg/vitamin D 800 IU daily (n = 15)
Estradiol 2 mg/dihydroprogesterone 10 mg for
4 days plus Ca/VitD (n = 15)
Risedronate 35 mg weekly plus Ca/VitD (n = 15)
ZA 4 mg iv. monthly for 3 months plus Ca/VitD
(n = 15)

60 women with stem cell transplant and ovarian
failure (age: 26 years; LS T-score: -1.4; FN
T-score: -1.5)

RCT (12 months)

[59]

60 subjects with b-thalassemia major and
hypogonadism (n = 30 women; age: 19 years)

Observational

LS BMD ↓ more in β-thalassemia groups than
controls (p < 0.001); LS BMD ↑ more in treated
than untreated group (p < 0.001); FN BMD ↓
more in untreated than treated group
(p < 0.001); FN BMD ↓ more in untreated vs
control group (p < 0.001)

Cyclic MPA 10 mg daily for 10 days with Ca
1000 mg
Cyclic MPA 10 mg daily for 10 days
Calcium 1000 mg daily
Double placebo
17-b estradiol 50 µg daily for 21 days with MPA
10 mg for 11 days each cycle (n = 10)
Untreated (n = 10)
Control (n = 10)

Ref.

[58]

Results

LS BMD: ↑1.7% MPA plus Ca (p = 0.004
compared with baseline); LS BMD: ↑1.7% in MPA
group; (p = 0.004 compared with baseline); LS
BMD no change in Ca group

Intervention

61 female athletes with menstrual irregularities
(age: 21–45 years)

Population

RCT (12 months)

Other

Study type
(length)

Table 2. Evidence for treatment of osteoporosis in young, premenopausal women (cont.).
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A review of osteoporosis management in younger premenopausal women –

women had a family history of osteoporosis
and 25% had experienced a fragility fracture.
Nearly 40% of the subjects had low calcium
intake (less than 500 mg/day) at baseline and
five patients smoked. Z-scores at baseline were
-2.04 at the LS and -1.47 at the FN, meeting the
definition for low bone mass. Over half of the
women increased their calcium intake through
diet rather than supplementation. All subjects
reported an increase in physical activity. A significant 1.9% increase was seen in LS BMD after
2 years (p = 0.021) and a 5.6% increase was seen
at the FN after 3 years (p = 0.04). The significant
increase at the FN is sufficient to reduce fracture
risk. No fractures were found during the study
period. This is the only study evaluating the
impact of treatment in idiopathic osteoporosis
and demonstrates that lifestyle changes can have
a significant impact on bone health.
A meta-analysis of resistance exercise on BMD
in premenopausal women did not find a statistically significant difference in LS or FN BMD
[14] . Walking, jumping and resistance exercises
have demonstrated a 1.2–2.6% increase in FN
BMD per year (p < 0.05), while resistance training and weight lifting demonstrated a 0.02%
increase in spinal BMD (p < 0.05) in healthy premenopausal women [15–17] . In a cohort study of
premenopausal women with rheumatoid arthritis
in Brazil (n = 71; average age: 38 years) with
29 healthy controls, women who were sedentary
were found to have a higher risk of osteopenia (no
hazard ratio reported; p = 0.044), while women
with moderate levels of activity had a relative risk
of 0.53 (95% CI: 0.37–0.76) [18] . No fractures
were reported during the 2-year course of the
study. Women with rheumatoid arthritis may
limit exercise due to pain and deformities associated with the disease process. Overall, these
results support the idea that an increase in exercise as tolerated can have a positive impact on
BMD in premenopausal women.
Treatment

The American Association of Clinical Endocrin
ologists recommends the bisphosphonates alendronate, risedronate and zoledronic acid, and denosumab as first-line treatments for postmenopausal
osteoporosis [19] . Ibandronate is recommended
as a second-line agent, raloxifene second or third
line, and calcitonin as a last-line therapy. Teri
paratide is recommended for women who have
failed bisphosphonates or have very high fracture
risk. Oral bisphosphonates are associated with
gastrointestinal (GI) adverse effects, such as
heartburn, indigestion and esophageal irritation.
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Intravenous (iv.) bisphosphonates are associated
with flu-like symptoms (fever and muscle aches),
especially with the first infusion in nearly onethird of women. Osteonecrosis of the jaw (ONJ)
is associated with bisphosphonate use, but is generally seen more often with iv. bisphosphonates
at higher doses than those used for osteoporosis.
Nausea and orthostatic hypotension have been
experienced with those women using teriparatide. Calcitonin injections may be accompanied
by nausea, local reactions, sweating and flushing.
Consideration of the risks of osteoporosis
treatment in premenopausal women must also
include risks for those women who are pregnant
or breastfeeding. Concerns for placental transfer
of bisphosphonates have resulted from rat studies
of fetal skeletal development and hypocalcemia.
Most case reports in humans have found no congenital abnormalities; however, bisphosphonates
carry a US FDA category C pregnancy risk, and
use of bisphosphonates without contraception
is not recommended in younger females [20] .
Case reports of two women with osteogenesis
imperfecta treated with bisphosphonates report
hypocalcemia in one newborn and club feet in
the other infant [10] . Concern also exists due to
the long duration of bisphosphonate incorporation in the bone [3] . One case series consisting
of four infants born to three mothers (one with
osteogenesis imperfecta and two with polyostotic
fibrous dysplasia) who received iv. pamidronate
prior to conception did not find any adverse
maternal or fetal effects [21] . The FDA pregnancy
risk for teriparatide is category C and iv. zoledronic acid is category D [3] . Selective estrogen
receptor modulators (SERMs) should not be
used in premenopausal women due to increased
bone loss [8] . Although use of oral contraceptives
have demonstrated mixed results in BMD of premenopausal women, the American College of
Rheumatology no longer recommends estrogen
as a treatment of osteoporosis in pre- or postmenopausal women [22,23] . It is important to note
potential limitations when evaluating choice of
drug therapy based on the FDA pregnancy risk
categories. The successive categories can be misleading and it may appear that there is increasing
risk of severity of malformation between categories. Furthermore, there is no distinction between
source of data (i.e., animal versus human) within
each category. The FDA pregnancy category
classification scheme also does not address that
the lack of treatment of certain comorbid conditions (e.g., diabetes mellitus, pregnancy-induced
hypertension and asthma) may outweigh the risk
of drug exposure to the fetus [24] .
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Anorexia nervosa

In women with AN, 20–50% develop osteo
porosis and 44% experience a fracture [9,25] .
The development of amenorrhea with AN leads
to a decrease in estrogen and bone loss within
12 months. Restoring body weight is the primary
treatment for osteoporosis associated with AN,
while recommending exercise may prove harmful
in those who have used exercise to purge. Most
studies of osteoporosis in AN have focused on
the replacement of estrogen as a treatment strategy. Bisphosphonate treatment in women with
a history of purging may be limited due to the
potential for esophageal ulcer development.
In an observational study of 75 women with
AN, the average age of included subjects was
24 years with a spine T-score of -1.8 and a hip
T-score of -1.4 [26] . Calcium and vitamin D
intake were not analyzed. Women were followed
from 6 months to 5 years. In the 45 women
who did not take oral contraceptives, resuming a menstrual cycle was associated with an
increase in spine BMD of 3.1% (p = 0.02), while
an increase in weight (to greater than 85% of
expected weight and/or a 10% increase) was
associated with an increase in hip BMD of
0.6% (p = 0.05). The use of oral contraceptives
was not associated with a significant change in
BMD at either site, whether or not weight was
gained or menses resumed. The authors summarized that weight restoration is more associated
with an increase in hip BMD, while the return
of menses is more associated with spinal BMD
improvement.
Adolescents with AN were followed for 1 year
after administration of hormone therapy to determine the medication’s effect on BMD (n = 38)
[27] . Baseline BMD was measured for each
woman after 1 year of amenorrhea and they were
treated with ethinyl estradiol 50 µg/norgestrel
0.5 mg daily. After 1 year, 22 women were available for analysis. The mean age at baseline was
17 years and the LS BMD T-score was -2.1. Calcium and vitamin D intake was not discussed.
After 1 year, the LS T-score in treated women
was -1.8; however, this was not significantly
different from baseline.
In a longitudinal study of 45 women with AN,
women with a T-score less than -2.5 were treated
with 17-b estradiol 0.5 mg percutaneously for
days 1–21 of each cycle and dydrogesterone
10 mg on days 11–21 for 2 years (n = 12) [25] . The
mean age of women was 25 years, and those with
osteoporosis had AN for 8 years, amenorrhea
for 7 years and Z-scores at LS of -2.3, FN -3.4
and total hip -3.4. Calcium and vitamin D were
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only given to those with noted deficiencies. No
significant changes in BMD were found at any
site in either the treatment or control group, and
there were no differences between the groups.
Although hormone therapy did not result in a
change in BMD, weight increase at 1 year did
result in a significant increase in LS and total hip
BMD (p = 0.04 for both), as well as a return of
the menstrual cycle at the spine, total hip and FN
(4%, p = 0.008; 3%, p = 0.05; and 3%, p = 0.04,
respectively). This study further demonstrates
the benefit of weight gain and return of menses
in women with AN. Hormone therapy did not
demonstrate a benefit, even in those women with
very low BMD.
An observational study of 50 women with AN
(average age: 16 years) demonstrated no benefit
of hormone therapy for increasing BMD [28] .
Women with anorexia were given the option,
along with their treatment team and family, of
standard treatment for AN (n = 28) or standard
treatment plus an oral contraceptive to prevent
bone loss (n = 22). Standard treatment involved
medical, nutritional and psychiatric approaches.
Five different oral contraceptives were used in
the women. All women received a multivitamin
with 400 IU of vitamin D daily and calcium
1200–1500 mg daily was given to those women
without adequate dietary calcium intake. At
baseline, women had experienced amenorrhea
for an average of 16 months and had a LS Z-score
of -1.58 and a FN T-score of -1.58 (Z-score not
reported). A significant difference between
the groups at baseline was a longer duration
of AN in the oral contraceptive group (15.7 vs
29.8 months; p = 0.02). After 1 year, women in
both groups gained 3–4 kg on average. However, no significant change in BMD at either the
LS or FN was observed. The authors note that
use of oral contraceptives in the absence of clear
benefit for BMD may mask the natural return
of menses that is often used to mark progress in
treating AN.
Another study evaluating the effect of estrogen/progesterone on BMD in young women
with AN randomized 48 women with amenorrhea to active drug (n = 22) or placebo (n = 26)
for 18 months. The mean age of the subjects
was 24 years. After 18 months, no difference
was found between the BMD of either group
[29] . Those who resumed menses had a 19.3%
increase in BMD. They also noted that women
with a lower weight at baseline had less recovery
in their bone mass. This study further supports
the role of weight gain and menses recovery over
hormone therapy in women with AN.
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A randomized, double-blind, placebo-controlled study of a triphasic oral contraceptive
in females with AN demonstrated a significant
change in LS BMD at 6 months; however, by the
conclusion of the study at 13 months, the difference was no longer significant [30] . Young women
were randomized to norgestimate/ethinyl estradiol (n = 53) or placebo (n = 59). The average
age of subjects included was 15 years and they
took a multivitamin with 500-mg calcium and
400-IU vitamin D. The baseline LS Z-score was
-0.8. After six cycles, the change in BMD at the
LS was 2.4% in the treatment group and 1% in
the placebo group (p = 0.013). After 13 cycles,
LS BMD was increased by 3.1% in the treatment group and 2.4% in the placebo group
(p = 0.268). There were no significant differences
in hip BMD at any time point. For those in the
treatment group, adverse events were reported as
follows: dysmenorrhea: 16.4%, abdominal pain:
11.5%, flu-like symptoms: 11.5% and sinusitis:
11.5%. Although this trial was shorter than
the others described, it demonstrates a possible
early benefit for hormone therapy on BMD but
no long-term benefit. With the development of
adverse events in several women, the risks of hormone therapy in these women likely outweigh
any potential benefit.
Overall, the evidence does not suggest a
benefit for estrogen or progesterone therapy in
young women with AN. Calcium and vitamin
D consumption was not analyzed in the majority of the trials; however, incorporating lifestyle
changes into the treatment of AN may prove beneficial. Other osteoporosis treatments have not
been evaluated in this population. The strongest
evidence for improvement of BMD in women
with AN is for weight gain and return of the
menstrual cycle.
Breast cancer

Breast cancer treatment with gonadotropinreleasing hormone analogs, tamoxifen and
aromatase inhibitors are associated with bone
loss [31] . Use of these medications results in a
hypogonadal state in women and contributes
to accelerated bone loss of up to 13% within
the first year of treatment, which is often more
severe than age-related bone loss. Studies have
estimated the bone loss to be 3–8% in the
LS and 2–4% in the total hip [32] . Although
tamoxifen is associated with increases in BMD
for postmenopausal women, it is associated with
a decrease in LS and hip BMD in premenopausal women due to its antagonistic effects
at the bone in the presence of premenopausal
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estrogen. Bisphosphonates have been evaluated
in this population for the prevention of bone
loss associated with breast cancer treatments.
Increased concerns exist for the development of
ONJ in cancer patients receiving bisphosphonates beyond that of women with osteoporosis.
A systematic review reported 6–10% of cancer
patients receiving bisphosphonates may develop
ONJ over 2–3 years [33] . The Belgian Bone Club
recommends that breast cancer patients treated
with aromatase inhibitors be treated with zoledronic acid 4 mg every 6 months [31] . Raloxifene
is not recommended in women with a history of
breast cancer who have been treated with tamoxifen due to cross-resistance [34] . Estrogens and
teriparatide are also not recommended by the
ASCO due to their potential to increase cancer
or metastases.
An open-label trial evaluating the effect of
zoledronic acid 4 mg iv. every 6 months in premenopausal women over age 40 (mean age:
44–45 years) who were undergoing chemotherapy for breast cancer (n = 112) was conducted
to evaluate the effect on BMD [35] . All women
took calcium 500 mg and vitamin D 1000 IU
daily. At baseline, the LS BMD was 1.09 g/cm2
and FN BMD was 0.88 g/cm2. After 12 months,
LS BMD decreased 1.1% in the zoledronic acid
group (n = 56) and by 7.5% in the observation
group (n = 56; p < 0.001 between groups), and
FN BMD increased by by 1.1% in the zoledronic
acid group and decreased by 3.4% in the observation group (p < 0.001 between groups). The
only adverse events reported were chills, arth
ralgia and myalgia in the zoledronic acid group
at the time of infusion. Although not a randomized controlled trial (RCT), these results suggest
a benefit for zoledronic acid in preserving LS
BMD and improving FN BMD in women with
breast cancer.
An additional, open-label, Phase III trial
evaluated the impact of zoledronic acid on bone
loss in premenopausal women (average age:
44–46 years) receiving treatment for hormoneresponsive breast cancer [36] . The Austrian Breast
and Colorectal Cancer Study Group Trial 12
examined the use of goserelin in combination
with aromatase inhibitors. Goserelin is associated with a 5% BMD loss in premenopausal
women and aromatase inhibitors are also associated with bone loss of 4–5% over 2 years. The
BMD substudy was performed to evaluate the
effects of combination treatment on bone health
and the impact of prevention on expected bone
loss. Premenopausal women (n = 401) were randomized to goserelin plus tamoxifen or goserelin
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plus anastrazole for 3 years. Each group was then
further randomized to those who would receive
zoledronic acid 4 mg iv. every 6 months (n = 204)
or not (n = 197). Calcium and vitamin D were
not discussed by the authors. At baseline, the
LS BMD was 1.0 g/cm2 and the hip BMD was
0.7 g/cm 2. Women who did not receive zoledronic acid experienced significant bone loss in
the LS over 3 years (-14.4%; p < 0.001), with a
T-score drop of -1.4; however, those who received
zoledronic acid did not demonstrate a significant
change in LS BMD over 3 years. Infusion reactions were the most commonly reported adverse
effect of zoledronic acid therapy and most often
occurred during the first infusion. Bone pain
was reported in 36%, arthralgia in 28% and
fever in 11% of women who received zoledronic
acid (p = 0.0003, p = 0.12 and p < 0.001, respectively compared with placebo). There were no
reports of ONJ or fractures for any women in the
trial. A follow-up was conducted 2 years after the
completion of the study (5 years from baseline),
and women who did not receive zoledronic acid
had continued declines in BMD, with a total of
6.6% loss at the LS (p < 0.01 from baseline) [37] .
Those in the zoledronic acid group saw a 4%
increase in LS BMD (p = 0.02) at the 60-month
mark. Two fractures were reported by women in
the placebo group, with none in the zoledronic
acid group; however, this was not statistically
significant (p = 0.242). In women at risk for
osteoporosis while being treated for breast cancer, the use of zoledronic acid for bone protection
was supported by evidence of stable BMD over
5 years compared with a sharp decline in the
placebo group.
Zoledronic acid was also evaluated for prophylaxis of bone loss in women receiving chemotherapy for breast cancer [32] . The iv. route
is preferred to minimize the GI adverse effects
of oral bisphosphonates in women receiving
chemotherapy. Premenopausal women with new
diagnoses of breast cancer were randomized to
zoledronic acid 4 mg iv. every 3 months (n = 50)
or placebo (n = 53) for 1 year while receiving
chemotherapy. The average age of participants
was 42 and all were given calcium 1000 mg daily
and vitamin D 400–800 IU daily. At baseline,
LS Z-scores were 0.2, FN Z-scores were 0.15 and
hip Z-scores were 0.17–0.25. After 12 months,
women in the placebo group experienced a
4.39% decrease in LS BMD compared with
0.6% in the zoledronic acid group (p < 0.05).
Similar results were seen for the FN (1.5% loss
in the placebo group compared with a gain of
0.4% in the zoledronic acid group; p < 0.05) and
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total hip (2.8 gain vs -0.12% loss, respectively;
p < 0.05). There were no reports of renal failure
or ONJ with bisphosphonate therapy; however,
47% complained of eye discomfort, which was
significantly different from placebo (p < 0.01). A
follow-up study of the women 12 months with
no intervention after the original study demonstrated significant continued bone loss in the following year at the LS and total hip for women
who received placebo (p < 0.001 for both) but
remained stable for those who had received zoledronic acid [38] . This study further describes the
benefit of zoledronic acid for osteoporosis prevention in women undergoing chemotherapy
for breast cancer. Adverse events experienced by
women in this population are similar to those
experienced by postmenopausal women.
Risedronate was evaluated for the prevention of bone loss in premenopausal women with
breast cancer in a placebo-controlled, doubleblind, randomized, Phase II trial of 216 women
(mean age: 43 years) [39] . All patients received
calcium 600 mg and vitamin D 400 IU daily.
Premenopausal women preparing to undergo
chemotherapy for breast cancer were randomized to risedronate 35 mg weekly (n = 108)
or placebo (n = 108) for 1 year. LS BMD at
baseline was 1.2 g/cm2. At 1 year, the change in
BMD at the LS was -4.3% for risedronate and
-5.4% for placebo; however, the difference was
not statistically significant. Adverse events were
similar in both groups. This differs from studies in postmenopausal women where risedronate
demonstrated an increase in BMD in women
with breast cancer undergoing chemotherapy
[40,41] . Another trial evaluating risedronate in
53 women with breast cancer and ovarian failure randomized women to risedronate 30 mg
daily for 2 weeks every 12 weeks for 2 years
(n = 27) or placebo (n = 26) [42] . After 2 years,
the BMD decreased in the placebo group but
increased in the risedronate group for a difference of 2.5% at the LS (p = 0.041) and 2.6% at
the FN (p = 0.029). Although these studies have
mixed results, overall, the data for the benefit of
risedronate are not as convincing as those for
zoledronic acid.
The overall data for breast cancer support the
role of bisphosphonates (particularly iv. bisphosphonate zoledronic acid) for the prevention of
osteoporosis associated with breast cancer treatment in premenopausal women. The safety profile in these women appears to be comparable
with that for postmenopausal women, despite
increased administration (every 6 months vs
every year).
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Glucocorticoid-induced osteoporosis

In the setting of glucocorticoid use, BMD is
noted to decrease precipitously after 3 months
of treatment up to 6 months with a slower, continued decline thereafter [23] . Glucocorticoids
contribute to osteoporosis by inhibiting osteoblast activity and decreasing calcium absorption
in the GI tract. The 2010 American College of
Rheumatology guidelines report an increased
risk of fracture in patients who currently receive
or in the past have received 2.5–7.5 mg daily of
prednisone or its equivalent. Fractures are noted
to develop in patients taking glucocorticoids
regardless of BMD and may occur in premenopausal women at higher BMDs than those seen
in postmenopausal women. Recommendations
are rated as follows: Level A (multiple RCTs or
meta-analysis); Level B (single RCT or non
randomized study); and Level C (expert consensus or case series). The authors recommend that
premenopausal women on glucocorticoid treatment with history of a prevalent fragility fracture should be treated for osteoporosis, with the
exception of those of child-bearing potential on
therapy for less than 3 months. They also recommend that women with no child-bearing potential taking prednisone ≥5 mg or its equivalent
daily for 1–3 months should take alendronate or
risedronate (Level A and studied for 3–4 years);
however those taking ≥7.5 mg or its equivalent
should receive zoledronic acid (Level B, studied
for 3 years) [43–45] . Those receiving glucocorticoid treatment for greater than 3 months may
take alendronate or risedronate (Level A), zoledronic acid or teriparatide (Level B) [23] . Women
with child-bearing potential taking prednisone
≥7.5 mg or its equivalent daily for more than
3 months should take alendronate (Level A), risedronate or teriparatide (Level C). These therapies were selected for their shorter half-lives. No
recommendations are made for those taking less
than 7.5 mg of prednisone or its equivalent for
greater than 3 months. All women, regardless of
dose or duration of glucocorticoid therapy, should
take calcium 1200–1500 mg/day and vitamin D
to achieve normal 25-hydroxyvitamin D levels,
or 800–1000 IU daily. Glucocorticoid use may
require the need for higher vitamin D doses in
order to maintain normal levels. The authors
noted a lack of data in premenopausal women
that limited the strength and number of recommendations. Alendronate and risedronate have
data demonstrating both improvement in BMD
and a decrease in vertebral fracture risk in patients
with glucocorticoid-induced osteoporosis (GIO).
The American College of Rheumatology (ACR)
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also recommends using the lowest dose of gluco
corticoid for the shortest duration possible in
order to minimize osteoporosis risk.
Following the revision of the ACR guidelines
in 2010, a Joint Guideline Working Group was
established by the International Osteoporosis
Foundation (IOF) and the European Calcified
Tissue Society (ECTS) to update GIO recommendations for Europe. The Joint IOF–ECTS
Working Group provided a framework for the
use of oral glucocorticoid therapy at any dose
for a period of 3 months or longer in male and
female patients aged 18 years and older [46] . Similar to the ACR guidelines, the Joint IOF–ECTS
Working Group position statement discussed epidemiology and pathophysiology of GIO as well
as the Fracture Risk Assessment Tool (FRAX®,
WHO, Sheffield, UK [101]). The Working Group
recommended alendronate, etidronate, risedronate, zoledronic acid and teriparatide as first-line
therapies for GIO in the majority of patients.
Even though recommendations from the ACR
were discussed in this position statement by the
IOF and the ECTS, the document explicitly
stated that local factors specific to each country
should be taken into account when considering
intervention.
As the evidence for each of the agents is well
established and supported by the guidelines,
trials that compare the various treatments are
reviewed below.
Infused versus oral bisphosphonates were
compared among different age groups and
menopausal state in a post hoc analysis of a trial
comparing zoledronic acid and risedronate [47] .
The authors felt that adherence would be greater
with an iv. infusion than with an oral medication and thus the chance of fractures may be
reduced [48] . Subjects ranging in age from 18 to
85 years with or at risk for GIO (taking pred
nisone 7.5 mg or equivalent daily) were randomized to zoledronic acid 5 mg iv. once or risedronate 5 mg by mouth daily for 1 year. Pregnant
women or those not using contraception were
excluded. All subjects also received calcium
1000 mg and vitamin D 400–1200 IU daily. At
baseline, 86 women aged less than 35 years and
231 women aged 35–50 years were included. For
menopausal state, 195 premenopausal women
were included. Baseline LS T-score was -1.3 to
-1.4 in the treatment group and -0.9 in the atrisk group. BMD was assessed at baseline and at
12 months, and was found to be increased at the
LS in women aged 35–50 years, with GIO more
for zoledronic acid than risedronate (p = 0.0041).
No significant difference was found in LS BMD
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in women less than 35 years of age. The authors
report that this may be due to the low sample
size of women in this age range (n = 86 out of
833 total). In the subgroup of premenopausal
women with GIO, zoledronic acid increased LS
BMD by 3.1% compared with 1.7% by risedronate, and in premenopausal women at risk
for GIO, zoledronic acid increased LS BMD by
1.8% compared with 0.7% by risedronate; however, these findings did not reach statistical significance. Total hip BMD increased significantly
more in the zoledronic acid group compared with
risedronate, both in women with GIO and those
at risk for GIO (1.34%; p = 0.025 and 1.45%;
p = 0.049, respectively). Differences between the
groups appeared at 6 months. The sponsor of the
study and manufacturer of zoledronic acid was
involved in all aspects of the design, data collection and reporting of results. In all HORIZON
(Health Outcomes and Reduced Incidence with
Zoledronic acid ONce yearly) participants, five
vertebral fractures developed in the zoledronic
acid group and three in the risedronate group;
however, the difference was not significant. No
cases of ONJ were reported during the study.
Adverse events were more common in the zoledronic acid group than the risedronate group
overall in both the treatment and prevention
groups (p = 0.0159 and 0.0272, respectively).
The significant zoledronic acid adverse reactions
included pyrexia 12–15%, myalgia 6–11%, vomiting 2–6%, influenza-like illness 6–7%, musculoskeletal chest pain 1–3%, sciatica 2–3% and
chills 2–4%. Overall, participants preferred the
iv. route for both convenience (81%) and satisfaction (78%). Based on the results of this large,
well-designed trial, zoledronic acid was superior
to risedronate at the hip and well tolerated in
younger women with GIO.
Alendronate was compared with activated
vitamin D in 201 patients with GIO over
18 months in a randomized, double-blind, double-dummy study [49] . Participants were included
if they planned to start or had started prednisone
7.5 mg or its equivalent daily within the previous 12 weeks and anticipated to stay on therapy
for at least 6 months due to a rheumatic condition. Subjects were randomized to alendronate
10 mg daily (n = 99) and alfacalcidol 1 µg daily
(n = 101), including seven and ten premenopausal women, respectively. The average age of
those in the study was 61 years with prednisone
doses of 22–23 mg/day. All subjects took calcium 1000 mg and vitamin D 400 IU daily. At
baseline, FN T-scores demonstrated low bone
mass (-1.2 to -1.4). After 18 months, LS BMD
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increased by 2.1% in the alendronate group and
declined by 1.9% in the alfacalcidol group, with
an absolute difference of 4% (95% CI: 2.4–5.5),
while hip BMD increased by 1.4% in the alendronate group and declined by 2.0% in the alfacalcidol group, for an absolute difference of 3.4%
(95% CI: 1.3–5.5). Over the course of the study,
three vertebral fractures developed in the alendronate group compared with 13 in the alfacalcidol
group (hazard ratio: 0.4; 95% CI: 0.1–1.4). Other
fractures occurred in two alendronate subjects
and three alfacalcidol subjects (hazard ratio: 0.7;
95% CI: 0.1–4). Adverse events were similar in
both groups, including GI complaints and hypocalcemia. This study definitively proves the superiority of GIO treatment with bisphosphonates
over that of activated vitamin D. Notably, this
study demonstrated a reduction in fractures with
bisphosphonate treatment.
The effects of teriparatide and alendronate on
LS BMD were compared in a subset of 67 premenopausal women (age: ≥21 years) with GIO
from a total of 428 [50] . Men and postmenopausal
women were also evaluated over 18 months.
Subjects were included if they had taken ≥5-mg
prednisone for ≥3 months and had a LS or hip
BMD T-score ≤-2.0 or ≤-1.0 with one fragility
fracture. Subjects were randomized to teriparatide 20 µg subcutaneously daily (n = 37) or
alendronate 10 mg by mouth daily (n = 30).
Calcium 1000 mg daily and vitamin D 800 IU
daily were also given over the course of the study.
The average age of women in the alendronate
group was 36 and 40 years in the teriparatide
group, LS T-scores of -2.6 and -2.4, total hip
T-scores of -1.8 and -1.7, and a history of daily
prednisone use 10 and 8 mg for 0.9 and 1.8 years,
with 28 and 33% having a history of fracture,
respectively. Indications for glucocorticoid use
included joint, autoimmune, respiratory and
bowel diseases. Five women in the teriparatide
group and nine women in the alendronate group
discontinued from the study (p = 0.06); most discontinued due to adverse events or subjects’ decision to withdraw. Premenopausal women treated
with teriparatide demonstrated a 7% increase in
LS BMD compared with 0.7% in the alendronate
group (p < 0.001) at 18 months. A 4% increase in
hip BMD in the teriparatide group versus 1% in
the alendronate group (p < 0.01) was also noted.
The differences were significant at 6 months and
maintained during the duration of the study. In
the subjects treated with alendronate, LS BMD
did not significantly differ from baseline at any
time point in the study. No new vertebral fractures were detected in any premenopausal women
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during the study period. Two nonvertebral fractures occurred in the teriparatide group and none
in the alendronate group; however, the difference
was not significant (p = 0.32). Adverse effects,
including influenza (10%), back pain (17%),
dyspnea (10%) and rash (10%), were reported
in the alendronate group, and nausea (14%),
influenza (11%), headache (11%), depression
(8%), vomiting (14%), dyspepsia (8%), cough
(8%) and myalgia (8%) were reported in the
teriparatide group. The authors speculated that
teriparatide demonstrated a greater impact on
BMD in premenopausal women due to the
mechanism of action directly altering the effects
of glucocorticoids on bone, whereas alendronate
does not mechanistically correct the effects of
glucocorticoids in the presence of estrogen in premenopausal women [5] . A final report was issued
after 36 months of treatment [51] . Although not
broken down by menopausal state, teriparatide
continued to significantly improve BMD at the
LS (11 vs 5.3%; p < 0.001), total hip (5.2 vs 2.7%;
p < 0.001) and FN (6.3 vs 3.4%; p < 0.001) compared with alendronate. A significant difference in
vertebral fractures was also noted after 36 months,
with 1.7% of participants in the teriparatide group
experiencing a fracture and 7.7% of participants
in the alendronate group experiencing a vertebral
fracture (p = 0.007). Nonvertebral fractures were
not significantly different. Adverse effects were
significantly greater for teriparatide in the following categories: nausea 17 versus 8% for alendronate (p = 0.007), dyspnea 7 versus 3% (p = 0.028),
insomnia 6 versus 1% (p = 0.017), viral infection 2
versus 0% (p = 0.023) and hypercalcemia 21 versus 7% (p < 0.001). Alendronate was significantly
greater for weight loss 4 versus 0% (p = 0.002).
Although bisphosphonates are commonly recommended for treatment of GIO, teriparatide has
demonstrated superiority at the hip and spine,
with a possible reduction in fractures compared
with alendronate.
Hormone therapy was compared with calcitriol
in 20 premenopausal women treated for systemic lupus erythematous with chronic steroids
[52] . Women in the trial had received more than
10 mg of prednisone daily and were randomized
to conjugated estrogen 0.625 mg daily days 1–21
of menstrual cycle and medroxyprogesterone acetate (MPA) 10 mg daily days 11–21, or calcitriol
0.5 µg daily. The average age of women at baseline was 37 years, they had experienced amenorrhea for 2 years, had osteopenia (LS BMD:
0.9 g/cm 2 and hip BMD: 0.7 g/cm 2) and all
participants took calcium 1000 mg daily. After
24 months, LS BMD decreased significantly
future science group
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by 1.74% (p < 0.05) in the calcitriol group but
increased by 2% in the hormone therapy group
(p < 0.05). The difference between groups at the
LS was significant (p < 0.03). No fractures were
reported over the course of the study. In women
with lupus, hormone therapy was superior to
calcitriol for treatment of GIO.
Overall, FDA-approved treatments for osteoporosis are superior to vitamin D alone. Teri
paratide and zoledronic acid have demonstrated
superiority to oral bisphosphonates in women
with GIO. Therapy should be based on ACR
recommendations, patient history and prescriber
preference.
Cystic fibrosis

With the increase in life expectancy for cystic fibrosis (CF) patients comes an increase in
the development of CF-related bone disease
[53] . Although the precise mechanism of bone
loss in CF patients is unknown, several factors
probably contribute, including lower peak bone
mass due to poor nutrition and physical activity, delayed puberty and hypogonadism, use of
glucocorticoids, and inflammatory cytokines.
Due to the increase in osteoporosis in this population, studies have been conducted to evaluate
appropriate treatments in these younger patients.
A randomized, double-blind, placebo-controlled trial of alendronate 10 mg daily was carried
out in CF patients with a T-score of less than or
equal to -1 at the spine or FN for 12 months [54] .
Forty-eight patients were included and equally
divided between the two groups. The alendronate
group contained nine females and the placebo
group contained 14. The average age of the participants was 27.5 years, the average LS T-score at
baseline was -1.785 and the Z-score was -1.695.
All subjects received 800 IU of vitamin D and
1000-mg calcium daily. The alendronate group
demonstrated a significant increase in BMD at
the hip (4.9 vs -1.8%; p < 0.001) and spine (2.8
vs -0.7%; p = 0.003) compared with placebo.
The authors noted a greater BMD response at
the spine in male subjects than female subjects.
No new vertebral fractures occurred during the
study period. While placebo subjects with baseline osteopenia continued to experience bone loss
after 1 year, subjects taking alendronate experienced a significant increase. This demonstrates
the efficacy of oral bisphosphonates in the CF
population; however, as adverse events were not
discussed, safety in this younger population still
needs to be evaluated.
Alendronate 70 mg weekly was evaluated in
56 patients, including 22 women with CF and
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a BMD T-score less than -1 in a randomized,
double-blind, placebo-controlled 12-month
trial [53] . All women also took vitamin D 800 IU
daily and calcium 500 mg from supplementation
and 500 mg from the diet daily. The average age
of the participants was 29 years and the average T-score at baseline in the LS was -1.6. After
12 months, LS BMD increased by 5.2% in the
alendronate group (n = 10) and decreased by
0.08% in the placebo group (n = 12), p < 0.001.
Hip BMD increased by 2.1% in the alendronate
group and decreased by 1.3% in the placebo
group, p < 0.001. There was no significant difference in the development of new vertebral fractures over the course of the study. Adverse events
were similar in both groups. This study further
demonstrates the role of alendronate in improving BMD in patients with CF and demonstrates
no additional safety risks in this population.
Although data are limited to small studies with
one active ingredient, the future looks promising
for the use of oral bisphosphonates in patients
with CF and demonstrated bone loss. Additional
research is needed to evaluate the long-term risks
in this population.
Kidney transplantation

Fracture risk for kidney transplant patients is as
high as 10% within the first 2 years, probably
due to the high doses of corticosteroids used to
prevent rejection. Post-transplant osteodystrophy is also due to the comorbity of diabetes in
many transplant patients, along with high doses
of loop diuretics. Zoledronic acid was evaluated
in 20 patients for prevention of bone loss following kidney transplantation in a randomized,
double-blind, placebo-controlled trial [55] . All
patients received methylprednisolone as part of
their antirejection regimen, with a cumulative
dose of 3 g over the course of the study. They also
received calcium citrate 1000 mg daily and daily
injections of 0.25–0.5 µg of activated vitamin D.
Participants were randomized to either zoledronic
acid 4 mg iv. at 2 weeks and again at 3 months
after transplant (n = 10) or placebo (n = 10). The
average age of participants was 49–55 years and
four out of the ten in each group were women.
LS Z-scores were -0.5 to -1 and FN Z-scores
were -0.8 to -1.1 at baseline. At 6 months, the LS
Z-score decreased by 0.27, while the zoledronic
acid group increased by 0.23. The authors report
that this was a significant difference from baseline
in each group; however, p-values were not listed.
At the FN, the Z-score decreased by 0.57 in the
placebo group (listed as significant) and remained
stable (a 0.02 increase) in the zoledronic acid
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group. A follow-up study 3 years after transplant
was performed and the Z-score in the placebo
group increased from -1.3 at 6 months to -0.2 at
3 years (p = 0.021) and from -1.6 to -1.2 in the
zoledronic acid group (p = 0.044) [56] . Overall,
the effect of zoledronic acid was temporary as
all groups experienced improvement in BMD
after 3 years. Two vertebral fractures occurred
in each group over 3 years. These results suggest
that osteoporosis prevention may not be required
in kidney transplant patients due to limited
long-term benefit on BMD or fractures.
iv. ibandronate was evaluated in 80 patients
(average age: 43 years) after kidney transplant,
a population which included 13 premenopausal
women [57] . Dietary counseling to encourage
1000 mg of daily calcium consumption was
provided and supplementation of 500 mg was
supplied for those with dairy intolerance. The
treatment group received ibandronate 1 mg iv.
before transplant (lower dose adjusted for renal
function) and 2 mg iv. every 3 months after transplant for a total of four infusions over 12 months
(n = 36 with six premenopausal women), while
other subjects were randomized to placebo
(n = 36 with seven premenopausal women). All
patients received cyclosporine, prednisone (average: 12–13 mg/day) and mycophenolate mofetil
to prevent rejection. At baseline, LS T-score was
-0.7 and FN T-score was -0.7. BMD decreased in
both groups at the LS after transplant; however, a
significantly greater percentage of bone loss was
noted in the control group (-0.9% ibandronate vs
-6.5% control; p < 0.0001). Different responses
at the FN were also noted (+0.5 ibandronate vs
-7.7% control at the FN; p < 0.0001). Benefits of
ibandronate were noted by the authors to occur at
all sites in the subgroup of premenopausal women.
Adverse effects of ibandronate included bone pain
and flatulence. This study demonstrated a benefit for frequent dosing of an iv. bisphosphonate,
although the long-term benefits have not been
elucidated.
In the setting of kidney transplant, data are
limited to support the use of any osteoporosis
treatment, including iv. bisphosphonates.
Other

In athletes with resulting menstrual cycle irregularities, cyclic MPA 10 mg daily for 10 days per
month was evaluated with and without calcium
1000 mg/day supplementation in a 12-month,
randomized, double-blind, placebo-controlled
trial. Women aged 21–45 years (n = 61) were
randomized to four groups (n = 16 in both MPA
groups, n = 15 in active calcium group and n = 14
future science group
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in placebo group). LS BMD was increased by
1.7% (p = 0.004) in both MPA groups, while
the calcium alone group experienced no change
in BMD [58] . Calcium supplementation may be
sufficient to minimize bone loss in female athletes with menstrual irregularities; however, additional evidence is needed to determine the role of
hormone therapy in this population.
Hormone therapy for treatment of hypo
gonadism associated with b-thalassemia major was
evaluated in an observational study of 60 patients,
including 30 women [59] . The average age of the
women was 19 years. Women were divided into
three groups: those receiving hormone therapy
with 17-b estradiol 50 µg daily for 21 days each
month and MPA 10 mg for 11 days each cycle
(n = 10), those untreated (n = 10) and a control
group of women without b-thalassemia (n = 10).
Women with b-thalassemia had decreased spine
BMD compared with controls (p < 0.001),
while estradiol/medroxyprogesterone-treated
women had increased BMD at the LS compared with untreated women with b-thalassemia
(p < 0.001). At the FN, the untreated
women had significantly lower BMD than
both the control group (p < 0.001) and the
estradiol/medroxyprogesterone-treated group
(p < 0.001). The authors concluded that osteoporosis is found at the LS and FN in untreated
women with thalassemia, while osteoporosis is
only present in the LS for women treated with
estradiol/medroxyprogesterone. The application
of these results is limited at this time due to the
limited population studied.
Various osteoporosis treatments were compared in women with ovarian failure after a
stem cell transplant [60] . Bone loss after stem
cell transplant is often associated with ovarian
failure. The authors report that standard treatment after stem cell transplant is for women
to receive calcium/vitamin D and hormone
replacement. Those who go on to develop osteoporosis are then treated with bisphosphonates.
Four groups of 15 women were randomized
to calcium 1000 mg/vitamin D 800 IU once
daily alone, estradiol 2 mg daily with dihydroprogesterone 10 mg for 14 days per month with
calcium/vitamin D, risedronate 35 mg weekly
with calcium/vitamin D or zoledronic acid 4 mg
iv. monthly for 3 months with calcium/vitamin
D for 12 months. The average age of women
in the trial was 26 years and baseline LS BMD
was -1.4, while FN BMD was -1.5. The calcium/vitamin D group experienced a significant decrease in BMD from baseline at the spine
(-4.3%; p < 0.05) and FN (-4.2%; p < 0.05),
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while the hormone therapy group remained
stable at all sites. The risedronate group demonstrated a significant increase in BMD at the
LS (5.8%; p < 0.05) and the zoledronic acid
group demonstrated a significant increase at the
LS (8.6%; p < 0.01) and FN (5.4%; p < 0.05).
Both bisphosphonates were significantly different from the calcium/vitamin D and hormone
treatment groups at both sites (p < 0.05), while
the zoledronic acid group experienced a significantly greater increase in BMD at the FN than
the risedronate group (5.4 vs 1.2%; p < 0.0001).
Vertebral fractures were found in five women at
baseline and three additional vertebral fractures
occurred during the 12 months. The study was
not powered to detect a difference in fractures.
Adverse effects occurred in six out of 15 women
in the hormone treatment group (headache and
breast tenderness), three out of 15 women in
the risedronate group (gastric pain) and flu-like
symptoms in 12 out of 15 women in the zoledronic acid group. Overall, nonhormonal osteoporosis treatment proved superior to placebo or
hormone replacement in women with ovarian
failure after stem cell transplant. Either oral or
iv. bisphosphonates may prove beneficial in this
population, although further studies on fracture
reduction should be carried out to determine
overall benefit.
Women with endometriosis who were treated
with gonadotropin-releasing hormone agonists
were randomized to treatment with parathyroid
hormone 40 µg subcutaneously daily (n = 20)
or placebo (n = 20), and followed for 6 months
[61] . Subjects (average age: 30 years) remained
on nafarelin 200 µg intranasally twice daily
throughout the study and were encouraged
to maintain daily consumption of calcium at
1200 mg through diet or supplements. LS BMD
was 0.8 g/cm2 and FN BMD was 0.9 g/cm2 at
baseline. At the LS, BMD decreased by 2.8%
from baseline (p < 0.001) in the placebo group,
while BMD in the treated group increased by
3.4% (p = 0.01). The difference between the two
groups reached significance (p < 0.001). No differences were noted between the groups at the
FN. Adverse effects in the parathyroid hormone
group were reported as follows: emotional instability 40%, nausea 35%, arthralgia 30%, weight
gain 15% and hair loss 10%. Due to the limited
evidence in this population and comparison with
placebo rather than other active treatments, no
recommendations can be made at this time. Multiple adverse events were associated with parathyroid hormone, which may also limit its use in
this population.
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Alendronate was evaluated in patients with
Crohn’s disease and low BMD (T-score less
than -1 in either the hip or spine) in a randomized, double-blind, placebo-controlled trial of
32 patients over 12 months [62] . Subjects were
randomized to alendronate 10 mg daily (n = 17)
or placebo (n = 15), with vitamin D 400 IU daily
and calcium if dietary intake was below 1000 mg
daily. LS BMD increased by 4.6% in the alendronate group and decreased by 0.9% in the placebo
group (p < 0.01). BMD was noted to increase
in premenopausal, as well as postmenopausal
women. In women with low T-scores and Crohn’s
disease, this study supports the use of alendronate
to improve BMD. Additional studies are needed
to ascertain the benefits for fracture prevention.
Calcitonin was evaluated in 28 premenopausal
women with recent oophorectomy to prevent bone
loss [63] . Women were randomized to 100 IU of
salmon calcitonin or placebo intramuscular every
other day starting 7 days after oophorectomy for

6 months, then all women were given active calcitonin for an additional 6 months. Additionally, the participants received calcium 500 mg
twice daily. While the placebo-treated patients
experienced a significant decrease in BMD after
12 months, the calcitonin-treated group did not
see a decline. Due to the small and limited studies, calcitonin cannot be recommended for prevention of bone loss in premenopausal women
with oophorectomy.
Conclusion

Osteoporosis diagnosis and management is clearly
defined for postmenopausal women, where the
risks for fractures and benefits of treatment have
been well studied. Osteoporosis discovery and
treatment in younger, premenopausal women
is less well defined due to the minimal risk of
fractures and lack of large RCTs. Premenopausal
osteoporosis is often a result of an underlying
condition or medication, and management is

Executive summary
Background
• Healthy premenopausal women experience a 0.25–1% loss in bone mineral density (BMD) annually after reaching peak bone mass,
and osteoporosis may be seen in 0.5% of premenopausal women.
• Many cases are due to secondary causes; however, the remaining cases are idiopathic in nature.
Diagnosis
• The International Society for Clinical Densitometry advocates the use of Z-scores rather than T-scores to determine BMD “below the
expected range for age.”
• The Z-score combined with risk factors, including a history of fragility fracture, is then used to make a diagnosis of osteoporosis in
younger women.
Osteoporosis prevention in young women
• The National Osteoporosis Foundation recommends that women aged 18–50 years should consume 1000 mg of calcium and 600 IU of
vitamin D daily.
• This, along with regular weight-bearing exercise, avoiding smoking and alcohol, and limiting caffeine consumption, are important
lifestyle factors to prevent or minimize osteoporosis in young women.
Anorexia nervosa
• Hormone therapy does not demonstrate benefit in young women with anorexia nervosa.
• The strongest evidence for improvement of BMD is for weight gain and return of the menstrual cycle.
Breast cancer
• The overall data for bone loss associated with breast cancer and chemotherapy support the role of bisphosphonates (particularly the
intravenous bisphosphonate zoledronic acid).
• The safety profile is similar to that for postmenopausal women, although risks in pregnancy and breastfeeding have not been
established.
Glucocorticoid-induced osteoporosis
• In younger women with glucocorticoid-induced osteoporosis, recommendations from the American College of Rheumatology and the
International Osteoporosis Foundation/European Calcified Tissue Society are available.
Cystic fibrosis
• Alendronate has demonstrated benefit in young women with cystic fibrosis and demonstrated bone loss.
• Additional research is needed to evaluate the long-term risks in this population.
• Data are limited to support the use of any osteoporosis treatment in other conditions not listed above.
• The evidence for treatment of osteoporosis in premenopausal women is not nearly as robust as that for postmenopausal osteoporosis.
Data are limited to recommend osteoporosis treatment outside the setting of a previous fracture or an underlying secondary cause.
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dependent on the underlying cause. Although
fracture risk in the premenopausal population
is low, women with secondary osteoporosis may
benefit from treatment. For young women with
AN, treatment of the underlying disease is associated with increases in BMD, while hormone therapy does not demonstrate a benefit. In the setting
of women undergoing chemotherapy for breast
cancer, zoledronic acid has shown promise for
improving BMD and may also prevent fractures.
GIO may be treated with either the bisphosphonates or teriparatide, since safety and efficacy of
these agents are well established in this population. Evidence is also supportive for alendronate
in women with CF-associated bone loss. In other
conditions, the data are limited to recommend
osteoporosis treatment in premenopausal women.
Future perspective

The American College of Rheumatology has
called for additional studies of the fracture risk
and risks of long-term osteoporosis treatment
in premenopausal women receiving glucocorticoids. Ongoing studies will provide additional
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